Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology [Seeking Alpha]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Seeking Alpha
Krystal Biotech's valuation is underpinned by VYJUVEK's blockbuster trajectory, high gross margins (94%), and disciplined R&D and SG&A spending. Phase 1 KB407 data in cystic fibrosis confirms molecular proof-of-concept, with a $2B+ opportunity targeting modulator-ineligible and suboptimal responder patients. Pipeline assets KB801 (neurotrophic keratitis) and KB803 (ocular DEB) provide differentiated, unmet-need-driven optionality, though risks remain from market size, trial outcomes, and regulatory shifts. Dr_Microbe/iStock via Getty Images Overview My last evaluation of Krystal 's stock ( KRYS ) was in November 2025 and followed its Q3 earnings. Krystal markets VYJUVEK–a topically applied gene therapy for wounds associated with dystrophic epidermolysis bullosa, or DEB. While I've always been bullish on VYJUVEK, in This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no pla
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Chardan Capital from $220.00 to $323.00. They now have a "buy" rating on the stock.MarketBeat
- Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Krystal Biotech Inc (KRYS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Krystal Biotech targets global VYJUVEK expansion with Italy launch in H2 2026 while maintaining 90%–95% gross margin outlook [Seeking Alpha]Seeking Alpha
KRYS
Earnings
- 2/17/26 - Beat
KRYS
Sec Filings
- 2/17/26 - Form 8-K
- 2/17/26 - Form 10-K
- 2/11/26 - Form 4
- KRYS's page on the SEC website